A Similar Phase I Study on the Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With Advanced NSCLC Treated With Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) Before and After Process Change
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2018
At a glance
- Drugs Toripalimab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Shanghai Junshi Biosciences
- 04 Sep 2018 Planned End Date changed from 30 Jul 2018 to 19 Dec 2018.
- 04 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 17 Mar 2018 Planned End Date changed from 30 Apr 2018 to 30 Jul 2018.